Skip to main content
SpringerLink
Log in

Cost Utility in Second-Line Metastatic Breast Cancer

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Launois R, Reboul-Marty J, Henry B, et al. A cost-utility analysis of second-line chemotherapy in metastatic cancer: docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996; 10(5): 504–21

    Article  PubMed  CAS  Google Scholar 

  2. Johnson SA, Harper P, Hortobagyi GN, et al. Vinorelbine: an overview. Cancer Treat Rev 1996; 22: 127–42

    Article  PubMed  CAS  Google Scholar 

  3. Pierre Fabre Medicament. Expert interviews conducted at 30 oncology centres in France (data on file)

  4. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment of advanced breast cancer. Ann Oncol 1994; 5: 423–6

    PubMed  CAS  Google Scholar 

  5. Alvarez A, Mickiewicz E, Caceres V, et al. Vinorelbine activity in heavily pre-treated breast cancer patients [abstract no. 250]. Proc Annu Meet Am Soc Clin Oncol 1996: 146

    Google Scholar 

  6. Barni S, Ardizzoia A, Bernado G, et al. Vinorelbine as single agent in pre-treated patients with advanced breast cancer. Tumori 1994; 80: 280–2

    PubMed  CAS  Google Scholar 

  7. Dalri P, De Vigili G, Fedrizzi F, et al. Vinorelbine as a second line treatment in anthracycline pre-treated advanced breast cancer patients [abstract no. P626]. 5th International Congress on Anti-Cancer Chemotherapy; 1995 Feb; Paris, 267

  8. Demicheli R, Terenziani M, Ferrari L, et al. Activity of vinorelbine in advanced breast cancer: preliminary results of a phase II trial. Eur J Cancer 1993; 29ASuppl. 6: A446

    Google Scholar 

  9. Dogliotti L, Gorzegno G, Bau MG, et al. Vinorelbine as second line treatment in anthracycline pre-treated advanced breast cancer patients: a phase II study. Eur J Cancer 1993; 29ASuppl. 6: A430

    Google Scholar 

  10. Extra JM, Leandri S, Dieras V, et al. Phase II study of vinorelbine in first and second line treatment of advanced breast cancer. In: Navelbine (vinorelbine) update and new trends. Paris: John Libbey Eurotext, 1991: 213–20

    Google Scholar 

  11. Fernandez O, Dodyk P, Fernandez L. Salvage chemotherapy with vinorelbine in advanced breast cancer [abstract no. AP379]. 5th International Congress on Anti-Cancer Chemotherapy; 1995 Feb; Paris, 231

  12. Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active anti-proliferative agent in pre-treated advanced breast cancer patients: a phase II study. J Clin Oncol 1994; 12: 2094–101

    PubMed  CAS  Google Scholar 

  13. Jones J-M, Winer E, Vogel C, et al. A multicenter, randomised trial of IV Navelbine versus IV Alkeran in patients with anthracycline-refractory advanced breast cancer [abstract no. 216]. Proc Am Soc Clin Oncol 1994; 13: 103

    Google Scholar 

  14. Nistico C, Ranuzzi M, Pace A, et al. Weekly vinorelbine in previously treated patients with advanced breast cancer: preliminary results [abstract no. 18]. Proc Am Soc Clin Oncol 1995; 14: 120

    Google Scholar 

  15. Tominaga T, Nomura Y, Adachi I, et al. Late phase II study of KW-2307 in advanced or recurrent breast cancer [in Japanese]. Jpn J Cancer Chemother 1994; 21: 809–16

    CAS  Google Scholar 

  16. Tresca P, Fumoleau P, Roche H, et al. Vinorelbine, a new active drug in breast carcinoma: results of an ARTAC phase II trial [abstract no. 66]. Breast Cancer Res Treat 1990; 16: 191

    Google Scholar 

  17. Weber B, Vogel C, Jones S, et al. A US multicenter phase II trial of Navelbine in advanced breast cancer [abstract no. 46]. Proc Am Soc Clin Oncol 1993; 12: 61

    Google Scholar 

  18. Goa K, Faulds D. Vinorelbine: a review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 1994; 5(3): 200–34

    Article  PubMed  CAS  Google Scholar 

  19. Food and Drug Administration for Drug Evaluation and Research Oncologic Drugs Advisory Committee. Study 048: multicentric randomised study of two doses of taxol in metastatic breast cancer. USA: Food and Drug Administration, 1993: 048F01-F017.CH3

    Google Scholar 

  20. Nabholtz JM, Gelmon K, Bontenbal M, et al. Randomised trial of two doses of Paclitaxel in metastatic breast cancer: an interim analysis [abstract no. 42]. Proc Am Soc Clin Oncol 1993; 12: 60

    Google Scholar 

  21. Donaldson C, Gerard K. Economics of health care financing: the visible hand. The MacMillan Press Ltd, 1994

  22. Mooney G. Economics, medicine and health care. Harvester Wheatsheaf, 1992

Download references

Author information

Authors and Affiliations

  1. Pierre Fabre Médicament, Boulogne-Billancourt, France

    Gilles Berdeaux & Patrick Hurteloup

Authors
  1. Gilles Berdeaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Hurteloup
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berdeaux, G., Hurteloup, P. Cost Utility in Second-Line Metastatic Breast Cancer. PharmacoEconomics 11, 492–495 (1997). https://doi.org/10.2165/00019053-199711050-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199711050-00012

Keywords

Search

Navigation